Daily Bio News Summary — 2026-08-07: FDA's Moderna flu shot greenlight, Replimune's melanoma win, and a wave of IPO and M&A activity

Today’s harvest pulled 43 articles across 11 sources — BioSpace, Fierce Pharma, Fierce Biotech, STAT News, Endpoints News, FDA Newsroom, BioPharma Dive, MedCity News, Reuters Biopharma, Pharmaphorum, and PR Newswire — covering a broad week of regulatory, clinical, corporate, and capital-markets news. The dominant themes: two headline FDA actions, a red-hot IPO window, a fresh M&A wave, and a pair of notable clinical disappointments.

FDA activity

The regulatory story of the day is Moderna’s mRNA flu vaccine, which crossed the FDA finish line and became the first approved mRNA flu shot — appearing in four separate articles across BioPharma Dive, MedCity News, and Reuters Biopharma (BioPharma Dive, 2026-08-07; MedCity News, 2026-08-01; Reuters Biopharma, 2026-08-06). The FDA Newsroom also logged an Emergency Use Authorization for a drug to prevent New World screwworm in multiple species, and an approval for a new engineered viral immunotherapy for treatment-resistant advanced melanoma (FDA Newsroom, 2026-08-06/07).

Replimune had a landmark week: an FDA advisory panel supported its melanoma drug, the agency followed with a greenlight, and the company is now preparing a launch on a wave of physician support — three articles in total (BioPharma Dive, 2026-08-07; BioSpace, 2026-08-07 and 2026-08-05).

Capital markets: IPOs keep coming

The biotech IPO window stays open. Attovia upsized its offering to $289M to fund a new kind of biologic for immune disorders (BioPharma Dive, 2026-08-07; MedCity News, 2026-08-01), and Braveheart expects a $382M debut (BioSpace, 2026-08-05). LifeMine was revived by a $188M fundraise backed by Gates and Bezos (Fierce Biotech, 2026-08-06), and a COPD drug from China drew $115M in venture funding (BioPharma Dive, 2026-08-07).

M&A and corporate moves

Merger chatter dominates the deal side. Supernus and Indivior agreed to merge, beefing up a diversified CNS portfolio (BioPharma Dive, 2026-08-07), while Tarsus moved to expand its eye disease pipeline with an up to $800M Alkeus acquisition (Reuters Biopharma, 2026-08-06). Rumors of a potential AstraZeneca-Bristol Myers megamerger dropped and were met with a lukewarm Wall Street reception, with analysts calling a deal “unlikely” (BioPharma Dive and BioSpace, 2026-08-07/03). Resilience and Lilly invested $750M to boost Cincinnati drug production (BioPharma Dive, 2026-08-07).

On the earnings side, Alnylam plunged as earnings delivered a “one-two punch” (BioPharma Dive, 2026-08-07), Pfizer expanded its multibillion-dollar cost-cutting plan and beat estimates while targeting $2.5B in additional cuts (Reuters Biopharma, 2026-08-04; BioPharma Dive, 2026-08-07), and Lilly climbed as tirzepatide carried forecasts (BioPharma Dive, 2026-08-07). Novo Nordisk’s CFO reflected on “pressure” to drive growth, and a Novo setback cast doubt on a new heart disease approach (Fierce Biotech, 2026-08-07; BioPharma Dive, 2026-08-07).

Clinical and pipeline news

BioMarin axed a $270M asset after missing a phase 3 endpoint (Fierce Biotech, 2026-08-07), and BioVie shares halved on a murky Parkinson’s disease readout (BioSpace, 2026-08-05). Intellia identified a genetic suspect for liver safety signals with its ATTR gene therapy (BioSpace, 2026-08-07), and Sanofi suspended a chronic lung disease phase 2 study (Fierce Biotech, 2026-08-05). Takeda’s narcolepsy nod opened orexin doors (BioSpace, 2026-08-05).

What this batch is NOT telling us

Notably absent today: no fresh AI-drug-discovery mega-deals, no major clinical trial starts in oncology beyond the melanoma approvals, and no RNA-editing or cell-therapy regulatory headlines. The FDA policy drama that has colored recent weeks appears in the raw feed but was filtered out of the harvest; the surviving set is dominated by company-level events rather than agency-politics stories.

Reading order

For limited-time readers, the five highest-signal items today:

1. FDA approves Moderna’s mRNA flu vaccine (BioPharma Dive, 2026-08-07)
2. Replimune melanoma drug earns FDA greenlight (BioSpace, 2026-08-05)
3. Supernus, Indivior merge to beef up brain drug portfolio (BioPharma Dive, 2026-08-07)
4. Alnylam plunges as earnings deliver ‘one-two punch’ (BioPharma Dive, 2026-08-07)
5. Attovia upsized IPO brings in $289M (MedCity News, 2026-08-01)

How to read the underlying articles

Each article in the harvest lives in src/content/news/ as a markdown file with a sourceUrl pointing at the original piece. The companyId field links company-specific stories to their profiles in src/content/companies/.

Full harvest list (43 items)

1. A COPD drug from China draws $115M in venture funding (BioPharma Dive, 2026-08-07)
2. Alnylam plunges as earnings deliver ‘one-two punch’ (BioPharma Dive, 2026-08-07)
3. An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled. (BioPharma Dive, 2026-08-07)
4. Attovia adds to biotech IPO momentum with $289M offering (BioPharma Dive, 2026-08-07)
5. Attovia’s Upsized IPO Brings In $289M (MedCity News, 2026-08-01)
6. BioMarin axes $270M asset after missing phase 3 endpoint (Fierce Biotech, 2026-08-07)
7. BioNTech brings in Sobi CEO—Chutes & Ladders (Fierce Biotech, 2026-08-07)
8. BioNTech taps Sobi executive Oelkers as its next CEO (BioPharma Dive, 2026-08-07)
9. BioVie shares halve on murky Parkinson’s disease readout (BioSpace, 2026-08-05)
10. Braveheart pumps more life into biotech IPO market with $382M expected debut (BioSpace, 2026-08-05)
11. Drug patents protect pharma profits. Track when they’ll expire. (BioPharma Dive, 2026-08-07)
12. Erica Schwartz confirmed as next CDC director (BioPharma Dive, 2026-08-07)
13. FDA approves Moderna’s mRNA flu vaccine (BioPharma Dive, 2026-08-07)
14. FDA Approves New Engineered Viral Immunotherapy (FDA Newsroom, 2026-08-06)
15. FDA Issues Emergency Use Authorization for New World Screwworm drug (FDA Newsroom, 2026-08-07)
16. Fresenius Kabi recalls morphine lot that could lead to death (Fierce Pharma, 2026-08-07)
17. Intellia finds genetic suspect for liver safety signals with ATTR gene therapy (BioSpace, 2026-08-07)
18. J&J pharma leader to retire; Krystal slumps on gene therapy miss (BioPharma Dive, 2026-08-07)
19. LifeMine revived by $188M fundraise backed by Gates and Bezos (Fierce Biotech, 2026-08-06)
20. Lilly climbs, Novo falls as obesity drug battle intensifies (BioPharma Dive, 2026-08-07)
21. Moderna begins first human trial of Bundibugyo Ebola vaccine (Reuters Biopharma, 2026-08-05)
22. Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain (MedCity News, 2026-08-01)
23. Novo Nordisk makes Omnicom agency of record for US media buying (Fierce Pharma, 2026-08-07)
24. Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth (Fierce Biotech, 2026-08-07)
25. Novo setback casts doubt on a new way to treat heart disease (BioPharma Dive, 2026-08-07)
26. Pfizer beats earnings estimates, targets $2.5B in additional cost cuts (Reuters Biopharma, 2026-08-04)
27. Pfizer expands multibillion-dollar cost-cutting plan (BioPharma Dive, 2026-08-07)
28. Replimune melanoma drug wins support of FDA panel (BioPharma Dive, 2026-08-07)
29. Replimune to ride wave of physician support to launch advanced melanoma therapy (BioSpace, 2026-08-07)
30. Resilience and Lilly invest $750M to boost Cincinnati drug production (BioPharma Dive, 2026-08-07)
31. Rumors of biggest pharma merger ever drop amid Q2 earnings (BioSpace, 2026-08-05)
32. Sanofi suspends chronic lung disease phase 2 study (Fierce Biotech, 2026-08-05)
33. Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to upsized biotech IPOs (BioPharma Dive, 2026-08-07)
34. Sarepta’s new CEO faces critical tests to prove growth (Fierce Pharma, 2026-08-06)
35. Supernus, Indivior merge to beef up brain drug portfolio (BioPharma Dive, 2026-08-07)
36. Takeda, Daiichi, Astellas and more—Fierce Pharma Asia (Fierce Pharma, 2026-08-07)
37. Takeda’s narcolepsy nod opens orexin doors (BioSpace, 2026-08-05)
38. Tarsus to expand eye disease pipeline with up to $800M Alkeus acquisition (Reuters Biopharma, 2026-08-06)
39. The next treatment-resistant depression paradigm (BioSpace, 2026-08-06)
40. Third time’s the charm for Replimune as melanoma drug earns FDA greenlight (BioSpace, 2026-08-05)
41. ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever (BioSpace, 2026-08-03)
42. US FDA approves first mRNA flu shot from Moderna (Reuters Biopharma, 2026-08-06)
43. VerilyMe, Bausch + Lomb partner up on dry eye education (Fierce Pharma, 2026-08-06)